<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04845165</url>
  </required_header>
  <id_info>
    <org_study_id>2020_50</org_study_id>
    <secondary_id>2020-A03167-32</secondary_id>
    <nct_id>NCT04845165</nct_id>
  </id_info>
  <brief_title>Study of Cortisol Metabolism in Familial Partial Lipodystrophy Type 2</brief_title>
  <acronym>LIPOCORT</acronym>
  <official_title>Study of Cortisol Metabolism in Familial Partial Lipodystrophy Type 2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Familial partial lipodystrophic syndromes are characterized by an increase in visceral&#xD;
      adipose tissue and an atrophy of subcutaneous adipose tissue. They are associated with a&#xD;
      severe metabolic syndrome especially when linked to the mutation of the R482 codon of the&#xD;
      LMNA gene (Familial partial lipodystrophy type 2, FPL2). Data in lipodystrophy induced by&#xD;
      antiretroviral therapy of HIV suggests an increase in the activity of 11β-hydroxysteroid&#xD;
      dehydrogenase type 1 (11bHSD1). This enzyme reactivates cortisone in cortisol in adipose&#xD;
      tissues and liver and has associated to obesity and type 2 diabetes mellitus. Hence, the&#xD;
      hypothesis is that in patients suffering from FPL2 with the R482 codon mutation of the LMNA&#xD;
      gene, there is an increase in the activity of HSD11B1 which could participate to the&#xD;
      metabolic phenotype of the disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2021</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>THE/(THF+αTHF) ratio measured in the 24h urine collections in patients</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>11BHSD1 expression in subcutaneous adipose tissue in patients</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cortisol metabolites excretion in patients</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of 11BHSD1 activity and metabolic parameters in patients</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Familial Partial Lipodystrophy Type 2</condition>
  <arm_group>
    <arm_group_label>Patients with FPL2 genetically confirmed</arm_group_label>
    <description>patients suffering with FPL2 with the R482 codon mutation of the LMNA gene.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Biopsy</intervention_name>
    <description>Biopsy of subcutaneous adipose tissue</description>
    <arm_group_label>Patients with FPL2 genetically confirmed</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      A 24 hours urine collection; Biopsy of subcutaneous adipose tissue&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients suffering from FPL2 with the R482 codon mutation of the LMNA gene treated in the&#xD;
        department of endocrinology at Lille University Hospital.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Familia partial lipodystrophy type 2 (FPL2) with the R482 codon mutation of the LMNA&#xD;
             gene&#xD;
&#xD;
          -  Social insured&#xD;
&#xD;
          -  Ability to give consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  urinary incontinence or inability to collect urine for 24 hours&#xD;
&#xD;
          -  moderate and severe kidney insufficiency&#xD;
&#xD;
          -  hepatic insufficiency&#xD;
&#xD;
          -  history of hypercortisolism or adrenal insufficiency&#xD;
&#xD;
          -  treatment interfering with the cortisol metabolism: taking oral or inhaled&#xD;
             glucocorticoids within the last 6 months&#xD;
&#xD;
          -  pregnant and lactating woman.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stéphanie ESPIARD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stéphanie ESPIARD, MD</last_name>
    <phone>0320445962</phone>
    <phone_ext>+33</phone_ext>
    <email>stephanie.espiard@chru-lille.fr</email>
  </overall_contact>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>April 13, 2021</study_first_submitted>
  <study_first_submitted_qc>April 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2021</study_first_posted>
  <last_update_submitted>April 13, 2021</last_update_submitted>
  <last_update_submitted_qc>April 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cortisol</keyword>
  <keyword>Lipodystrophy 3</keyword>
  <keyword>Hydroxysteroid 11-β dehydrogenase 1 (HSD11B1)</keyword>
  <keyword>Insulin Resistance</keyword>
  <keyword>Hypertriglyceridemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lipodystrophy, Familial Partial</mesh_term>
    <mesh_term>Lipodystrophy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

